Skip to Main Content

Paper Details

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Cancer Immunol Immunother
5
2022
Author NameAffiliation
Bo GaoBlacktown and Westmead Hospitals
  • 1 - 1

Datasets

Release 1.2